Igc Pharma Inc
(IGC)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 06-2014 | 03-2014 | 12-2013 | 09-2013 | 06-2013 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -1,210 | -3,043 | -1,553 | -1,248 | -632 |
| Depreciation Amortization | 149 | 712 | 445 | 297 | 149 |
| Income taxes - deferred | N/A | N/A | 5 | 3 | 2 |
| Accounts receivable | -115 | 375 | 96 | -6 | 47 |
| Accounts payable and accrued liabilities | 25 | -454 | -6 | 6 | 29 |
| Other Working Capital | -211 | -561 | -516 | -174 | -131 |
| Other Operating Activity | 794 | 1,228 | 662 | 706 | 293 |
| Operating Cash Flow | $-567 | $-1,742 | $-867 | $-416 | $-244 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -292 | 3 | N/A | N/A | N/A |
| Net Acquisitions | 167 | N/A | N/A | N/A | N/A |
| Investing Cash Flow | $-125 | $3 | $0 | $0 | $0 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | -316 | -22 | -143 | 0 | N/A |
| Debt Repayment | -3 | N/A | 0 | -102 | 0 |
| Common Stock Issued | 2,917 | 1,758 | 639 | 202 | 0 |
| Financing Cash Flow | $2,598 | $1,736 | $496 | $100 | $0 |
| Exchange Rate Effect | 21 | -35 | -253 | -22 | -170 |
| Beginning Cash Position | 1,027 | 1,064 | 1,064 | 1,064 | 1,064 |
| End Cash Position | 2,953 | 1,027 | 441 | 727 | 652 |
| Net Cash Flow | $1,926 | $-38 | $-624 | $-338 | $-413 |
| Free Cash Flow | |||||
| Operating Cash Flow | -567 | -1,742 | -867 | -416 | -244 |
| Capital Expenditure | -292 | -9 | 0 | 0 | N/A |
| Free Cash Flow | -859 | -1,751 | -867 | -416 | -244 |